TAIPEI, July 25, 2024 /PRNewswire/ -- Merdury Biopharmaceutical Corporation (Merdury) (Taipei Exchange Stock Code: 6932) announced today that it has signed a Memorandum of Understanding (MOU) with Health2Sync, Asia's largest chronic disease management platform. In this collaboration, the two parties aim to enhance the clinical evidence supporting the superior pharmacokinetic profile of oral semaglutide when delivered by Merdury's StackDose™ technology. As a GLP-1 agonist, semaglutide has demonstrated remarkable efficacy in treating diabetes and obesity. Its exceptional weight reduction capabilities led to FDA approval for weight management in the US in 2021, and it is rapidly gaining popularity in the US and around the world.
Taiwan-based startup Merdury Biopharmaceutical Corporation has signed a Memorandum of Understanding (MoU) with Health2Sync, Asia's largest chronic disease management platform. In this collaboration, the two parties aim to enhance the clinical evidence supporting the superior pharmacokinetic profile of oral semaglutide when delivered by Merdury's StackDose technology.